{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:02:00Z","timestamp":1784869320559,"version":"3.55.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Understanding concerns about recurrence or metastasis after nephrectomy and preferences for adjuvant therapy among patients with renal cell carcinoma (RCC) is important for facilitating shared decision-making between patients and physicians. We conducted a web-based survey to assess anxiety about recurrence or metastasis after nephrectomy and to describe treatment perspectives and preferences regarding adjuvant therapy among patients with RCC in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this non-interventional, cross-sectional descriptive study, patient-reported data were collected using a web-based questionnaire. Eligible patients with RCC who had undergone radical or partial nephrectomy were recruited through the Rakuten Panel. Anxiety about recurrence or metastasis was assessed using a visual analog scale. The survey was conducted between 27 October and 7 November 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 447 eligible patients participated in the survey, of whom 410 (91.7%) were men. The most frequent age group was patients in their 60s (42.5%), followed by those in their 70s (29.1%) and 50s (19.0%). The mean anxiety score regarding recurrence or metastasis after nephrectomy was 3.8 (SD 2.8) on a visual analog scale (VAS; 0\u20139). Among the 387 patients (86.6%) who reported anxiety about recurrence or metastasis immediately after surgery, 243 (62.8%) reported that information provided by medical professionals, including physicians and nurses, was the most effective in reducing anxiety. More than half of the participating patients (61.7%) preferred to receive adjuvant therapy that has been shown to reduce or delay the risk of recurrence or metastasis, even in the absence of evidence for prolonging life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study describes patient-reported anxiety about recurrence or metastasis after nephrectomy and reported perspectives on adjuvant therapy among Japanese patients with RCC. The findings suggest that information provided by medical professionals may be perceived as helpful in reducing anxiety about recurrence or metastasis. In a hypothetical scenario, a substantial proportion of respondents indicated that they would prefer adjuvant therapy when it was presented as reducing or delaying recurrence or metastasis, even without an overall survival benefit. These findings should be interpreted with caution but may help inform shared decision-making and patient-centered postoperative care in RCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1812667","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:31Z","timestamp":1784867011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anxiety about recurrence or metastasis after nephrectomy and perspectives on and preferences for adjuvant therapy among patients with renal cell carcinoma in Japan: a cross-sectional web-based survey"],"prefix":"10.3389","volume":"16","author":[{"given":"Nobuyuki","family":"Hinata","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University","place":["Hiroshima, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Miyajima","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Yasuoka","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Tokudome","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kojima","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sona-Sanae","family":"Aoyagi","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Japan G.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Japan G.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ito","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD K.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"B4","unstructured":"CANCER TODAY"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102207","article-title":"Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives","volume":"97","author":"Larroquette","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32144","article-title":"Adjuvant therapy in renal cell carcinoma","volume":"125","author":"Gul","year":"2019","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/01.ju.0000165572.38887.da","article-title":"Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system","volume":"174","author":"Lam","year":"2005","journal-title":"J Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","unstructured":"Pembrolizumab as postoperative therapy indication for RCC has been approved in Japan"},{"key":"B11","unstructured":"FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","unstructured":"FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21488","article-title":"Adult cancer survivors: how are they faring","volume":"104","author":"Baker","year":"2005","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-013-0272-z","article-title":"Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies","volume":"7","author":"Simard","year":"2013","journal-title":"J Cancer Surviv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000497233","article-title":"Long-term side effects of adjuvant therapy in primary breast cancer patients: results of a web-based survey","volume":"14","author":"Haidinger","year":"2019","journal-title":"Breast Care (Basel)"},{"key":"B17","unstructured":"Pre- and postoperative psychological assessment and decision-making for adjuvant chemotherapy in patients with resected lung cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.591","article-title":"MO43-6 UPRISE study: anxiety in patients with urothelial cancer in postoperative period-relation to patient demographics","volume":"35","author":"Morishima","year":"2024","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-023-03411-3","article-title":"Use of the visual analogue scale for health state valuation: a scoping review","volume":"32","author":"\u00c5str\u00f6m","year":"2023","journal-title":"Qual Life Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0316159","article-title":"Validation of visual analog scales of mood and anxiety at the workplace","volume":"19","author":"Dutheil","year":"2024","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.223","article-title":"Patients' and oncologists' views on the treatment and care of advanced ovarian cancer in the U.K.: results from the ADVOCATE study","volume":"108","author":"Jenkins","year":"2013","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7196","article-title":"Cross-sectional study of therapy-related expectations\/concerns of patients with metastatic renal cell carcinoma and physicians in Japan","volume":"13","author":"Kimura","year":"2024","journal-title":"Cancer Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:32Z","timestamp":1784867012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1812667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1812667"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1812667","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1812667"}}